Challenges and advances in gene therapy approaches for neurodegenerative disorders

Aneesh Donde, Philip C. Wong, Liam L. Chen

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: The recent approval of Spinraza (nusinersen), an antisense oligonucleotide, by U.S. Food and Drug Administration to treat patients with spinal muscular atrophy, has reignited interests of researchers in designing and testing new gene therapy approaches to treat neurological disorders, in particular, to curb neurodegenerative diseases of the central nervous system which represent an ever-increasing public health burden to today’s society. Conclusion: This review highlights several key factors to be taken into consideration to design successful preclinical and clinical gene therapy experiments with respect to the vehicle of delivery and the route of administration to CNS-specific targets, with an additional focus on antisense oligonucleotide therapy and recent clinical trial developments.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalCurrent Gene Therapy
Volume17
Issue number3
DOIs
StatePublished - Jun 1 2017

Keywords

  • Antisense oligonucleotide
  • Central nervous system
  • Clinical trial
  • Gene therapy
  • Neurodegenerative disorder
  • Viral vectors

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Challenges and advances in gene therapy approaches for neurodegenerative disorders'. Together they form a unique fingerprint.

Cite this